Welcome to the Marble Center for Cancer Nanomedicine

Dr. Bob Langer

Celebrating National Nanotechnology Day

Dr. Sangeeta Bhatia's commentary for National Nanotechnology Day featured by the National Academy of Sciences. Click here to read the commentary.

Dr. Bob Langer

Dr. Bob Langer receives the 2017 Kabiller Prize in Nanoscience and Nanomedicine from Northwestern

Dr. Robert S. Langer, David H. Koch Institute Professor at MIT and member of the Marble Center for Cancer Nanomedicine, is the recipient of the $250,000 Kabiller Prize in Nanoscience and Nanomedicine from Northwestern. The prize recognizes the people designing the technologies that will drive innovation in nanomedicine and also to educate others as to the field’s great promise for helping society. Click here for the press release.

The Convergence Scholars Program

The Convergence Scholars Program

We are proud to announce the launch of the Convergence Scholars Program (CSP), a pilot initiative at the Koch Institute's Marble Center aimed at cultivating in postdoctoral trainees an integrative vision of science and technology. Click here for more information.

Converging on cancer at the nanoscale

Converging on cancer at the nanoscale

Marking its first anniversary, the Koch Institute’s Marble Center for Cancer Nanomedicine goes full steam ahead. See the article in MIT News here.

Koch Institute Summer Symposium: Convergence of Science and Engineering in Cancer

MIT’s Koch Institute for Integrative Cancer Research held on June 16th its Annual Cancer Research Symposium: Convergence of Science and Engineering in Cancer. Convergence—the merging of historically distinct disciplines such as engineering, physics, computer science, chemistry, mathematics, and the life sciences—has created extraordinary opportunities in cancer research and care. Leaders in this emerging field discussed innovative new approaches and technologies to better detect, monitor, treat, and prevent cancer. See the article from the Boston Globe here and the KI press release here.

Nanoscale dream team: 3 MIT professors use tiniest of tools against cancer

Drs. Belcher, Bhatia, and Hammond are innovating at the tiniest scale—developing tools to see, target and kill cancer cells before they can cause any harm. See article here.

A high-magnification micrograph of an ovarian clear cell carcinoma

New technology can detect tiny ovarian tumors

Synthetic biomarkers could be used to diagnose ovarian cancer months earlier than now possible. See article here. Photo credit: Nephron/CC BY-SA 3.0.

Tiny Trojan Horses

Tiny Trojan Horses: Tumor-penetrating nanoparticles infiltrate cancer cells

Winner of the 2017 Koch Institute Public Galleries (click here to see other winners). This image shows biocompatible nanoparticles (yellow) inside clusters of pancreatic cancer cells (pink). The particles’ two-peptide uptake system—one to target the tumor, the second to penetrate it—was specially designed to overcome known difficulties in treating pancreatic cancer. Funded in part by the Marble Center for Cancer Nanomedicine at MIT's Koch Institute. Photo credit: Liangliang Hao, Srivatsan Raghavan, Emilia Pulver, Jeffrey Wyckoff, Sangeeta Bhatia.

Tethered nanoparticles make tumor cells more vulnerable

Tethered nanoparticles make tumor cells more vulnerable

New strategy could improve performance of some immune-based drugs. See article herePhoto credit: Second Bay Studios.

Robert Langer, The Delivery Man

Robert Langer, The Delivery Man

The downfall of many drugs is that they are not taken regularly or as prescribed. Robert Langer has developed a polymer that could solve this problem. See article herePhoto credit: Nick D Burton; original article by Kathryn Nave from WIRED Magazine.

Image gallery for National Nanotechnology Day

Image gallery for National Nanotechnology Day

In honor of the first annual National Nanotechnology Day, the Koch Institute for Integrative Cancer Research at MIT presents an interactive peek into how researchers across the MIT campus are using nanomaterials to explore and improve the world. Source: The Koch Institute for Integrative Cancer Research at MIT.

A Golden Opportunity for Drug Delivery

A Golden Opportunity for Drug Delivery

This image explores how exotic materials can be used to deliver drugs on-demand using light-triggered devices fabricated from integrated polymer nanotechnologies. Source: Erik Dreaden of the Hammond Laboratory at the Koch Institute for Integrative Cancer Research at MIT.

Suit Your Cell: Designing Custom Biomaterials

Suit Your Cell: Designing Custom Biomaterials

This image shows sixteen polymer spots from an automated screening experiment. Source: Asha K. Patel of the Anderson Laboratory at the Koch Institute for Integrative Cancer Research at MIT.

Target Practice: Improving Gene Therapy with Nanotechnology

Target Practice: Improving Gene Therapy with Nanotechnology

This image shows nanoparticles delivering siRNA to the cytoplasm of cervical tumor cells. Source: Omar Khan and Edmond Zaia of the Langer and Anderson Laboratories at the Koch Institute for Integrative Cancer Research at MIT.

Therapeutic Cells Loaded with Synthetic Nanoparticles

Therapeutic Cells Loaded with Synthetic Nanoparticles

Source: Matthias T. Stephan, James J. Moon, Soong Ho Um, Anna Bershteyn and Darrell J. Irvine of the Irvine Laboratory at the Koch Institute for Integrative Cancer Research at MIT.

Virus-Templated Copper Nanowires with Fused Silver Nanoparticles

Virus-Templated Copper Nanowires with Fused Silver Nanoparticles

Source: John Burpo and Angela M. Belcher of the Biomolecular Materials Laboratory at the Koch Institute for Integrative Cancer Research at MIT.

Blood, Heat, and Tumors: Improving Drug Delivery with Gold Nanorods

Blood, Heat, and Tumors: Improving Drug Delivery with Gold Nanorods

This image, submitted by Alex Bagley, shows gold nanorods in a living tumor. Source: Alex Bagley from the Laboratory for Multiscale Regenerative Technologies at the Koch Institute for Integrative Cancer Research at MIT.

The Marble Center for Cancer Nanomedicine aims to galvanize the MIT research community in efforts to have an indelible impact on cancer diagnosis and care.